Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Xinnaoxin capsule in preparation of antidepressant

A technology of antidepressants and capsules, applied in the field of medicine, to achieve the effects of reducing immobility time, antagonizing body temperature drop, and increasing content

Active Publication Date: 2014-01-08
GANSU CHEEZHENG TIBETAN MEDICINE CO LTD
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the effect has not been reported in antidepressants

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Xinnaoxin capsule in preparation of antidepressant
  • Application of Xinnaoxin capsule in preparation of antidepressant
  • Application of Xinnaoxin capsule in preparation of antidepressant

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0010] Effects of Xinnaoxin Capsules on Depressive Behavior in Behavioral Hopelessness Model Mice

[0011] 1 Materials and methods

[0012] 1.1 Materials

[0013] 1.1.1 Main Drugs and Reagents

[0014] Xinnaoxin Capsules, the content is tan powder, 0.5g / capsule, batch number: 120803 Sanpu Pharmaceutical Co., Ltd.;

[0015] Fluoxetine hydrochloride tablets (Changzhou Siyao Pharmaceutical Co., Ltd., 20120308).

[0016] 1.1.2 Experimental animals

[0017] Clean grade ICR mice, male, weight (20±2) g, Nantong University Experimental Animal Center, certificate number: SCXK (Su) 2008-0010. The animals were housed in separate cages, maintained a 12-h circadian rhythm, at a room temperature of 22±1°C, and had free access to water and food.

[0018] 1.1.3 Main experimental instruments

[0019] Mine behavior tester for mice (homemade, 30cm in diameter, 20cm in height, 19 equal parts at the bottom);

[0020] Mouse forced swimming behavior tester (self-made, height 50cm, diameter 20...

Embodiment 2

[0050] Effects of Acute Administration of Xinnaoxin Capsules on MAO-B Activity in Brain Tissue of Mice

[0051] 1 Materials and methods

[0052] 1.1.1 Main Drugs and Reagents

[0053] Xinnaoxin Capsules, the content is tan powder, 0.5g / capsule, batch number: 120803 Sanpu Pharmaceutical Co., Ltd.;

[0054] Fluoxetine Hydrochloride Tablets (Changzhou Siyao Pharmaceutical Co., Ltd., 20120308);

[0055] BCA protein concentration determination kit (Beiyuntian Biotechnology Research Institute, P0012)

[0056] Monoamine oxidase (MAO) test kit (Nanjing Jiancheng Bioengineering Institute, A034)

[0057] 1.1.2 Experimental animals

[0058] Clean grade ICR mice, male, weight (20±2) g, Nantong University Experimental Animal Center, certificate number: SCXK (Su) 2008-0010. The animals were housed in separate cages, maintained a 12-h circadian rhythm, at a room temperature of 22±1°C, and had free access to water and food.

[0059] 1.1.3 Main experimental instruments

[0060] Mouse fo...

Embodiment 3

[0081] Effects of Xinnaoxin Capsules on the Behavior of Drug-Induced Depression Model Mice

[0082] 1 Materials and methods

[0083] 1.1 Materials

[0084] Main Drugs and Reagents

[0085] Xinnaoxin Capsules, the content is tan powder, 0.5g / capsule, batch number: 120803 Sanpu Pharmaceutical Co., Ltd.;

[0086] Fluoxetine Hydrochloride Tablets (Changzhou Siyao Pharmaceutical Co., Ltd., 20120308);

[0087] Normal saline (0.86%);

[0088] 5-HTP: produced by Hangzhou Zhongxiang Chemical Co., Ltd., batch number: CAC071205;

[0089] 5-Hydroxytryptophan (5-Hydroxy-DL-tryptophan, 5-HTP), Fluka Company;

[0090] Apomorphine (Apomorphine Hydrochloride Hemihydrate), Sigma Company;

[0091] Reserpine: The injection is a product of Tianjin Jinyao Co., Ltd., batch number 1107171.

[0092] Noradrenaline Bitartrate Injection (Noradrenaline Bitartrate Injection), Shanghai Hefeng Pharmaceutical Co., Ltd., batch number 110703.

[0093] 1.2 Experimental animals

[0094] Clean grade ICR m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a Xinnaoxin capsule in preparation of an antidepressant. According to experimental studies, the Xinnaoxin capsule can substantially reduce dead time during tail suspension and forced swimming of behavioral despair model mice; according to open field experiments, spontaneous activities of the mice are not influenced while dead time is substantially decreased, which prompts that the Xinnaoxin capsule has a certain anti-depression effect. Meanwhile, the Xinnaoxin capsule can substantially inhibit activity of monoamine oxidase and increase the content of a monoamine neurotransmitter in a synaptic cleft, which proves that the Xinnaoxin capsule has the anti-depression effect. Moreover, the Xinnaoxin capsule can substantially antagonize decrease of body temperature of the mice caused by reserpine and apomorphine and increase exogenous toxicity given to NE, which reveals that the capsule has the anti-depression effect. The anti-depression effect of the capsule is realized through improvement of the level of the monoamine neurotransmitter in the synaptic cleft.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of Xinnaoxin capsules in the preparation of antidepressants. Background technique [0002] Depression is characterized by emotional disorders, which not only affects the work, study and life of patients, hinders their social functions, but is more likely to lead to suicide and endanger the lives of patients. With the fierce competition in the society and the accelerated pace of work, the number of patients with depression will also show an upward trend [1]. According to the latest survey and statistical analysis of the World Health Organization, the global incidence of depression is about 3.1%, while the incidence in developed countries is close to 6%. % of the rate increase, has become a frequently-occurring disease, a common disease. [0003] Depression is a group of heterogeneous diseases with different etiology and pathogenesis. Its symptoms and signs are...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/815A61K9/48A61P25/24
Inventor 邹存生马俊仓贺生玲张国清夏彬
Owner GANSU CHEEZHENG TIBETAN MEDICINE CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com